![Scott Morenstein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Morenstein
Direktor/Vorstandsmitglied bei
Primmune Therapeutics, Inc.
Profil
Scott D.
Morenstein was the founder of Seaview Securities LLC, founded in 2010, holding the title of Member.
Current jobs include Managing Director at Blackstone Multi-Asset Advisors LLC since 2022, Director at Palvella Therapeutics, Inc., Director at Primmune Therapeutics, Inc., Director at Antios Therapeutics, Inc., Director at Molecular Templates OpCo, Inc., and Director at Avenge Bio, Inc. Former jobs include Director at Synta Pharmaceuticals Corp.
from 2015 to 2016, Independent Director at Celator Pharmaceuticals, Inc. from 2013 to 2016, Director at Gemin X Pharmaceuticals US, Inc., Managing Director at Caxton Advantage Venture Partners, Managing Director at Caxton Alternative Management LP from 2013 to 2022, Managing Director at Valence Life Sciences LLC from 2012 to 2013, Director at Velicept Therapeutics, Inc., Independent Director at Molecular Templates, Inc. from 2017 to 2023, and Principal at Lehman Brothers, Inc. in 2002.
Education includes an undergraduate degree from the University of Pennsylvania, conferred in 1998, and an MBA from Harvard Business School.
Aktive Positionen von Scott Morenstein
| Unternehmen | Position | Beginn |
|---|---|---|
Primmune Therapeutics, Inc.
 Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops orally administered toll-like receptor for cancer immunotherapy | Direktor/Vorstandsmitglied | - |
Molecular Templates OpCo, Inc.
 Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Functions as an investment holding company | Direktor/Vorstandsmitglied | - |
Antios Therapeutics, Inc.
 Antios Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biopharmaceutical company focused on development of innovative therapies to treat and cure viral diseases | Direktor/Vorstandsmitglied | - |
Palvella Therapeutics, Inc.
 Palvella Therapeutics, Inc. BiotechnologyHealth Technology Engages in developing new therapeutic agents for diseases suffered by patients that lack any treatment choices | Direktor/Vorstandsmitglied | - |
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as an immuno-oncology company | Direktor/Vorstandsmitglied | - |
Blackstone Multi-Asset Advisors LLC
 Blackstone Multi-Asset Advisors LLC Investment ManagersFinance Blackstone Multi-Asset Advisors invests in companies located in the United States. The firm focuses on companies operating across a broad range of sectors and industries. It provides financing for buyout transactions. | Private Equity Investor | 01.02.2022 |
Ehemalige bekannte Positionen von Scott Morenstein
| Unternehmen | Position | Ende |
|---|---|---|
| MOLECULAR TEMPLATES, INC. | Direktor/Vorstandsmitglied | 01.03.2023 |
Caxton Alternative Management LP
 Caxton Alternative Management LP Investment ManagersFinance CAM Capital seeks to achieve long-term compounded growth of their portfolio using a fundamentally-driven, opportunistic investment strategy. The firm invests in both public and private markets, across the capital structure. CAM Capital’s investments include public and private equity, corporate credit, real estate, and global macro instruments. Their geographic focus is primarily in the Americas and Western Europe. | Vorstandsvorsitzender | 01.02.2022 |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel pharmaceutical products | Direktor/Vorstandsmitglied | 22.07.2016 |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Scott Morenstein
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
83
Beziehungen ersten Grades
18
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 18 |
|---|---|
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel pharmaceutical products | Health Technology |
Seaview Securities LLC
 Seaview Securities LLC Investment Banks/BrokersFinance Provides investment banking services focused on the life sciences industry | Finance |
Celator Pharmaceuticals, Inc.
 Celator Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat acute myeloid leukemia and AML with myelodysplasia in children & adults | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gemin X Pharmaceuticals US, Inc.
 Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Develops cancer therapeutic products | Health Technology |
Caxton Advantage Venture Partners
 Caxton Advantage Venture Partners Investment ManagersFinance Caxton Advantage Venture Partners invests primarily in companies in the pharmaceutical and biotechnology sectors | Finance |
Lehman Brothers, Inc. /Istanbul Division/
 Lehman Brothers, Inc. /Istanbul Division/ Investment ManagersFinance Provides investment banking and securities services | Finance |
Caxton Alternative Management LP
Caxton Alternative Management LP Investment ManagersFinance CAM Capital seeks to achieve long-term compounded growth of their portfolio using a fundamentally-driven, opportunistic investment strategy. The firm invests in both public and private markets, across the capital structure. CAM Capital’s investments include public and private equity, corporate credit, real estate, and global macro instruments. Their geographic focus is primarily in the Americas and Western Europe. | Finance |
Valence Life Sciences LLC
 Valence Life Sciences LLC Investment ManagersFinance Valence Life Sciences seeks investment opportunities in companies located in the United States. The firm targets companies operating in the fields of private and micro-cap public drug development companies. It provides financing for late stage capital requirements. | Finance |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blackstone Multi-Asset Advisors LLC
Blackstone Multi-Asset Advisors LLC Investment ManagersFinance Blackstone Multi-Asset Advisors invests in companies located in the United States. The firm focuses on companies operating across a broad range of sectors and industries. It provides financing for buyout transactions. | Finance |
Velicept Therapeutics, Inc.
 Velicept Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Manufactures biopharmaceutical products | Health Technology |
Molecular Templates, Inc.
 Molecular Templates, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biopharmaceutical company | Commercial Services |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Engages in developing new therapeutic agents for diseases suffered by patients that lack any treatment choices | Health Technology |
Primmune Therapeutics, Inc.
Primmune Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops orally administered toll-like receptor for cancer immunotherapy | Commercial Services |
Antios Therapeutics, Inc.
Antios Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biopharmaceutical company focused on development of innovative therapies to treat and cure viral diseases | Commercial Services |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as an immuno-oncology company | Health Technology |
